EAGLE PHARMACEUTICALS
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 135
- Market Cap
- $61.6M
- Website
- http://www.eagleus.com
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
- Conditions
- Pneumonia, Bacterial
- Interventions
- Drug: PlaceboDrug: CAL02
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT05776004
- Locations
- 🇺🇸
UCSF Hospital, Fresno, California, United States
🇺🇸UF Health Shands Hospital, Gainesville, Florida, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
- Conditions
- Exertional Heat Stroke
- Interventions
- Drug: Ryanodex and Standard of CareOther: Standard of Care
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03600376
- Locations
- 🇸🇦
Mina al Jisr Hospital, Mina, Saudi Arabia
🇸🇦King Faisal Hospital, Mecca, Saudi Arabia
🇸🇦Mina Al-Wadi Hospital, Mina, Saudi Arabia
Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT03324061
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
- Conditions
- Drug Toxicity Psychotropic Agents Psychostimulants
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03189433
- Locations
- 🇺🇸
CrowdRx Medical Office- Moonrise Festival, Baltimore, Maryland, United States
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02513095
A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
- Conditions
- Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
- Interventions
- Drug: Test Product (Bendamustine)
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02162888
- Locations
- 🇺🇸
Greenville Hospital System University Medical Center, Greenville, South Carolina, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Regional Cancer Care Associates, Cherry Hill, New Jersey, United States